HPTN Publications

Sugarman J, Corneli A, Donnell D, Liu TY, Rose S, Celentano D, Jackson B, Aramrattana A, Wei L, Shao Y, Liping F, Baoling R, Dye B, Metzger D . Are there adverse consequences of quizzing during informed consent for HIV research?. J Med Ethics. 2011, 37: 693-7 PMCID: 3200567
Sugarman J, Grace WC . Ethics and the standards of prevention in HIV prevention trials - comment. AIDS. 2010, 24: 2298-9 PMID:20736687
Sugarman J, Mayer KH . Ethics and pre-exposure prophylaxis for HIV infection. J Acquir Immune Defic Syndr. 2013, 63: S135-9 PMCID: 3728665
Sugarman J, Rose SM, Metzger D . Ethical issues in HIV prevention research with people who inject drugs. Clin Trials. 2014, 11: 239-45
Sugarman J, Stalter R, Bokoch K, Liu T, and Donnell D, Donnell D . Positive Social Impacts Related to Participation in an HIV Prevention Trial Involving People Who Inject Drugs. IRB: Ethics & Human Research. 2015, 37: 17-19
Susan H Eshleman, Estelle Piwowar-Manning, Mariya V. Sivay, Barbara Debevec, Stephanie Veater, Laura McKinstry, Linda Gail Bekker, Sharon Mannheimer, Robert M. Grant, Margaret A. Chesney, Thomas J. Coates, Beryl A. Koblin, Jessica M. Fogel . Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol. 2018, 99-100: 67-70
Sweat M, Morin S, Celentano D, Mulawa M, Singh B, Mbwambo J, Kawichai S, Chingono A, Khumalo-Sakutukwa G, Gray G, Richter L, Kulich M, Sadowski A, Coates T . Community-based intervention to increase HIV testing and case detection in people aged 16–32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infectious Disease. 2011, 11: 525-32 PMCID: 3156626
T Gamble, B Branson, D Donnell, HI Hall, G King, B Cutler, S Hader, D Burns, J Leider, AF Wood, KG Volpp, WM El-Sadr . Design of the HPTN 065 (TLC-Plus) Study: A Study to Evaluate the Feasibility of an Enhanced Test, Link-to-Care, Plus Treat Approach for HIV Prevention in the United States. Clin Trials. 2017, 14: 322-332
Tabet S, Sanchez J, Lama J, Goicochea P, Campos P, Rouillon M, Cairo JL, Ueda L, Watts D, Celum C, Holmes K . HIV, syphilis and heterosexual bridging among Peruvian men who have sex with men. AIDS. 2002, 16: 1271-1277
Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, van Damme L, Celum CL . Safety and Acceptability of Penile Application of 2 Candidate Topical Microbicides: BufferGel and PRO 2000 Gel: 3 Randomized Trials in Healthy Low-Risk Men and HIV-Positive Men. J Acquir Immune Defic Syndr. 2003, 33: 476-83
Tabet SR, Surawicz C, Horton S, Paradise M, Coletti AS, Gross M, Fleming TR, Buchbinder S, Haggitt RC, Levine H, Kelly CW, Celum CL . Safety and toxicity of nonoxynol-9 gel as a rectal microbicide. Sex Transm Dis. 1999, 26: 564-71
Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, Sinkala M, Martinson FE, Kafulafula G, Msamanga G, Emel L, Adeniyi-Jones S, Goldenberg R . A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS. 2006, 20: 1313-21 PMID: 16816561
Taha TE, Dallabetta GA, Hoover DR, Chiphangwi JD, Mtimavalye LA, Liomba GN, Kumwenda NI, Miotti PG . Trends of HIV-1 and sexually transmitted diseases among pregnant and postpartum women in urban Malawi. AIDS. 1998, 12: 197-203
Taha TE, Graham SM, Kumwenda NI, Broadhead RL, Hoover DR, Markakis D, van Der Hoeven L, Liomba GN, Chiphangwi JD, Miotti PG . Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics. 2000, 106: E77
Taha TE, Hoover DR, Dallabetta GA, Kumwenda NI, Mtimavalye LA, Yang LP, Liomba GN, Broadhead RL, Chiphangwi JD, Miotti PG . Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998, 12: 1699-706
Taha TE, Hoover DR, Kumwenda NI, Fiscus SA, Kafulafula G, Nkhoma C, Chen S, Piwowar E, Broadhead RL, Jackson JB, Miotti PG . Late postnatal transmission of HIV-1 and associated factors. J Infect Dis. 2007, 196: 10-14 PMID: 17538877
Taha TE, James MM, Hoover DR, Sun J, Laeyendecker O, Mullis CE, Kumwenda JJ, Lingappa JR, Auvert B, Morrison CS, Mofensen LM, Taylor A, Fowler MG, Kumenda NI, Eshleman SH . Association of recent HIV infection and in-utero HIV-1 transmission. AIDS. 2011, 25: 1357-1364 PMCID: 3263827
Taha TE, Kumwenda N, Gibbons A, Hoover D, Lema V, Fiscus S, Mukiibi J, Liomba G, Broadhead R . Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS. 2002, 16: 851-8
Taha TE, Kumwenda NI, Hoover DR, Biggar RJ, Broadhead RL, Cassol S, van der Hoven L, Markakis D, Liomba GN, Chiphangwi JD, Miotti PG . Association of HIV-1 load and CD4 lymphocyte count with mortality among untreated African children over one year of age. AIDS. 2000, 14: 453-9
Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, Nour S, Chen S, Liomba G, Miotti PG, Broadhead RL . Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting; a randomized controlled trial. JAMA. 2004, 292: 202-9
Taha TE, Kumwenda, Broadhead, Hoover, Graham, Hoeven, LV, D, Markakis, Liomba, GN, Chiphangwi, JD, Miotti, PG, Kumwenda NI, Broadhead RL, Hoover DR, Graham SM, Van Der Hoeven . Mortality after the first year of life among HIV infected and uninfected children. Ped Infect Dis J. 1999, 18: 689-94
Tedrow VA, Zelaya CE, Kennedy CE, Morin SF, Khumalo-Sakutukwa G, Sweat MD, Celentano DD . No "Magic Bullet": Exploring community mobilization strategies used in a multi-site community based randomized controlled trial: Project Accept (HPTN 043). AIDS Behav. 2012, 16: 1217-26 PMCID: 3400971
Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vanqa N, Smith PC, Floyd S, Bock P, Ayles H, Beyers N, Young A, Donnell D, Fidler S, Hayes R, Hauck K, on behalf of the HPTN 071(PopART) Study Team . Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. Lancet Glob Health. 2017, 5: e1133-e1141
Thompson CG, Cohen MS, Kashuba AD . Antiretroviral pharmacology in mucosal tissues. J Acquir Immune Defic Syndr. 2013, 63: S240-7 PMCID:3951793
Tien PC, Chiu T, Latif AS, Ray S, Batra M, Contag CH, Zejenah L, Mbizvo M, Delwart EL, Mullins JI, Katzenstein DA . Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol. 1999, 20: 147-53
Tieu HV, Liu TY, Hussen S, Connor M, Wang L, Buchbinder S, Wilton L, Gorbach P, Mayer K, Griffith S, Kelly C, Elharrar V, Phillips G, Cummings V, Koblin B, Latkin C; HPTN 061 . Sexual Networks and HIV Risk among Black Men Who Have Sex with Men in 6 U.S. Cities. PLoS One. 2015, 10: e0134085
Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME . Translational research insights from completed HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2013, 63: S150-4
Tobian AA, Gaydos C, Gray RH, Kigozi G, Serwadda D, Quinn N, Grabowski MK, Musoke R, Ndyanabo A, Nalugoda F, Wawer MJ, Quinn TC . Male circumcision and Mycoplasma genitalium infection in female partners: a randomised trial in Rakai, Uganda. Sex Transm Infect. 2014, 90: 150-4
Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M, Musoke P, Eshleman SH . Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses. 2010, 26: 563-8 PMCID: 2875950
Towler WI, Church JD, Eshleman JR, Fowler MG, Guay LA, Jackson JB, Eshleman SH . Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq). AIDS Res Hum Retroviruses. 2008, 24: 1209-13. PMCID:2562759
Towler WI, James MM, Ray SC, Wang L, Donnell D, Mwatha A, Guay L, Nakabiito C, Musoke P, Jackson JB, Eshleman SH . Analysis of HIV diversity using a high-resolution melting assay. AIDS Res Hum Retroviruses. 2010, 26: 913-8 PMCID: 2920076
Valsamakis A . Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007, 20: 426-39
van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K . Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001, 26: 21-7
Van Der Pol B, Williams JA, Taylor SN, Cammarata CL, Rivers CA, Body BA, Nye M, Fuller D, Schwebke JR, Barnes M, Gaydos CA . Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system. J Clin Microbiol. 2014, 52: 885-9
van Rooyen H, McGrath N, Chirowodza A, Joseph P, Fiamma A, Gray G, Richter L, Coates T . Mobile VCT: Reaching Men and Young People in Urban and Rural South African Pilot Studies (NIMH Project Accept, HPTN 043). AIDS Behav. 2013, 17: 2946-53 PMCID: 3597746
Venkatesh KK, Madiba P, De Bruyn G, Lurie MN, Coates TJ, Gray GE . Who gets tested for HIV in a South African urban township? Implications for test and treat and gender-based prevention interventions. JAIDS. 2011, 56: 151-65 PMCID: 3137901
Vermund SH, Fidler SJ, Ayles H, Beyers N, Hayes RJ. . Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr. 2013, 63: S221-7 PMCID: 3739051
Vermund SH, Hodder SL, Justman JE, Koblin BA, Mastro TD, Mayer KH, Wheeler DP, El-Sadr WM . Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 2010, 50: S149-55 PMCID: 2862583
Viljoen L, Ndubani R, Bond V, Seeley J, Reynolds L, Hoddinott G, on behalf of the HPTN 071 (PopART) Study Team . Community narratives about women and HIV risk in 21 high-burden communities in Zambia and South Africa. Int J Womens Health. 2017, 9: 861-870
Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, Martinez-Maza O, Bream JH . The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015, 29: 463-71
Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR 3rd, Cohen MS, Freedberg KA. . Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. NEJM. 2013, 369: 1715-25 PMCID: 3913536
Watson-Jones D, Wald A, Celum C, Lingappa J, Weiss HA, Changalucha J, Baisley K, Tanton C, Hayes RJ, Marshak JO, Gladden RG, Koelle DM . Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials. J Clin Microbiol. 2010, 48: 3496-503 PMCID: 2953087
Watts DH, Brown ER, Maldonado Y, Herron C, Chipato T, Reddy L, Moodley D, Nakabiito C, Manji K, Fawzi W, George K, Richardson P, Zwerski S, Coovadia H, Fowler M; HPTN 046 Protocol Team . HIV Disease Progression in the First Year After Delivery Among African Women Followed in the HPTN 046 Clinical Trial. J Acquir Immune Defic Syndr. 2013, 64: 299-306 PMCID: 3800257
Wei L, Chen J, Rodolph M, Beauchamp G, M 0226 Sse B, Li R, Wang S, Ruan Y, Lai S, Zhang L, Zhou F, Rose SM, Perdue T, Shao Y, Jackson JB . HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China. Subst Abus. 2006, 274: 53-61 PMID: 17347126
Welte A, McWalter TA, Laeyendecker O, Hallet TB . Using tests for recent infection to estimate incidence: Problems and Prospects for HIV. Euro Surveill. 2010, 15: pii: 19589 PMCID: 2937566
Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O . Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS One. 2013, 8: e55525 PMCID: 3577851
Westheimer EF, Urassa W, Msamanga G, Baylin A, Wei R, Aboud S, Kaaya S, Fawzi WW . Acceptance of HIV Testing Among Pregnant Women in Dar-es-Salaam, Tanzania. J Acquir Immune Defic Syndr. 2004, 37: 1197-1205
Wheeler DP, Fields SD, Beauchamp G, Chen YQ, Emel LM, Hightow-Weidman L, Hucks-Ortiz C, Kuo I, Lucas J, Magnus M, Mayer KH, Nelson LE, Hendrix CW, Piwowar-Manning E, Shoptaw S, Watkins P, Watson CC, Wilton L . Pre-exposure prophylaxis initiation and adherence among Black men who have sex with men (MSM) in three US cities: results from the HPTN 073 study. J Int AIDS Soc. 2019, 22: e25223
Williams C, Eisenberg M, Becher J, Davis-Vogel A, Fiore D, Metzger D . Racial disparities in HIV prevalence and risk behaviors among injection drug users and members of their risk networks. J Acquir Immune Defic Syndr. 2013, 63: S90-4 PMCID: In Process
Williams JK, Wilton L, Magnus M, Wang L, Wang J, Dyer TP, Koblin BA, Hucks-Ortiz C, Fields SD, Shoptaw S, Stephenson R, O'Cleirigh C, Cummings V; HIV Prevention Trials Network 061 Study Team . Relation of Childhood Sexual Abuse, Intimate Partner Violence, and Depression to Risk Factors for HIV Among Black Men Who Have Sex With Men in 6 US Cities. Am J Public Health. 2015, 105: 2473-81
Wilson CM, Gray G, Read JS, Mwatha A, Lala S, Johnson S, Violari A, Sibiya PM, Fleming TR, Koonce A, Vermund SH, McIntyre J . Tolerance and Safety of Different Concentrations of Chlorhexidine for Peripartum Vaginal and Infant Washes: HIVNET 025. J Acquir Immune Defic Syndr. 2004, 35: 138-43
Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW . Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res Hum Retroviruses. 1998, 14: 925-37
Wind-Rotolo M, Durand C, Cranmer L, Reid A, Martinson N, Doherty M, Jilek BL, Kagaayi J, Kizza A, Pillay V, Laeyendecker O, Reynolds SJ, Eshleman SH, Lau B, Ray SC, Siliciano JD, Quinn TC, Siliciano RF . Identification of Nevirapine-Resistant HIV-1 in the Latent Reservoir after Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV-1. J Infect Dis. 2009, 199: 1301-9 PMCID:2703715
WM El-Sadr, D Donnell, G Beauchamp, HI Hall, LV Torian, B Zingman, G Lum, M Kharfen, R Elion, FM Gordin, V Elharrar, D Burns, A Zerbe, T Gamble, B Branson . Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065). 2017
Wong LH, Van Rooyen H, Modiba P, Richter L, Gray G, McIntyre JA, Schetter CD, Coates T . Test and Tell: Correlates and Consequences of Testing and Disclosure of HIV Status in South Africa (HPTN 043 Project Accept). JAIDS. 2009, 50: 215-22 PMCID:2729272
Woodsong C . Covert use of topical microbicides: implications for acceptability and use. Perspect Sex Reprod Health. 2004, 36: 127-31
Woodsong C, Alleman P, Musara P, Chandipwisa A, Chirenje M, Martinson F, Hoffman I . Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe. AIDS Behav. 2012, 16: 785-90 PMCID: 3658446
Woody G, VanEttne-Lee ML, McKirnan D, Donnell D, Seage G, Gross M . Substance Use Among Men who have Sex with Men: Comparison with a National Household Survey. J Acquir Immune Defic Syndr. 2001, 27: 86-90
Woody GE, Donnell D, Seage GR, Metzger D, Marmor M, Koblin BA, Buchbinder S, Gross M, Stone B, Judson FN . Non-injection substance use correlates with risky sex among men having sex with men: data from HIVNET. Drug Alcohol Depend. 1999, 53: 197-205
Young SD, Hlavka Z, Modiba P, Gray G, Rooyen HV, Richter L, Szekeres G, Coates T . HIV-Related stigma, social norms, and HIV testing in Soweto and Vulindlela, South Africa: National Institutes of Mental Health Project Accept (HPTN 043). J Acquir Immune Defic Syndr. 2010, 55: 620-4 PMCID: 3136617
Zhang Y, Fogel JM, Guo X, Clarke W, Breaud A, Cummings V, Hamilton EL, Ogendo A, Kayange N, Panchia R, Dominguez K, Chen YQ, Sandfort T, Eshleman SH . Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. AIDS. 2018, 32: 1301-1306
Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Mâsse B, Ma J, Gu Y, He Y, Rui B, Wang J, Poundstone K, Jiang Y, Brooks Jackson J, Shao Y . Demographic characteristics and risk behaviors associated with HIV positive injecting drug users in Xinjiang, China. J Infect. 2007, 54: 285-90 PMID: 16831464
Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Mâsse B, Ma J, Rui B, Wang J, Liu M, Wang Y, He Y, Poundstone K, Jiang Y, Jackson JB, Shao Y . HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int J Infect Dis. 2007, 11: 318-23 PMID: 17321184
Zhang Y, Sivay MV, Hudelson SE, Clarke W, Breaud A, Wang J, Piwowar-Manning E, Agyei Y, Fogel JM, Hamilton EL, Selin A, MacPhail C, Kahn K, Gomez-Olive FX, Hughes JP, Pettifor A, Eshleman SH . Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068. J Acquir Immune Defic Syndr. 2018, 79: 315-322
Zulu I, Schuman P, Musonda R, Chomba E, Mwinga K, Sinkala M, Chisembele M, Mwaba P, Kasonde D, Vermund SH . Priorities for Antiretroviral Therapy Research in Sub-Saharan Africa: A 2002 Consensus Conference in Zambia. J Acquir Immune Defic Syndr. 2004, 36: 831-34 PMCID: 2745050